Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apyx Medical Corporation - Common Stock (NQ:APYX)

2.490 -0.060 (-2.35%)
Delayed Quote Updated: 9:32 AM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Apyx Medical Corporation - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Comparing the Use of Renuvion to a Competing Technology Following Liposuction or Body Contouring Procedures
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation Reports Second Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation Reports First Quarter 2024 Financial Results; Reaffirms Full Year 2024 Financial Outlook
From Apyx Medical Corporation
Via Business Wire
Apyx Medical Corp. (NASDAQ: APYX) Leading the Way in Friday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
Apyx Medical Corporation Announces Board Leadership Transition
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation Showcases New Data and Treatment Insights at the Renuvion® Users’ Summit
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2023 Financial Results; Introduces Full Year 2024 Financial Outlook
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2023 Financial Results on March 21, 2024
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation Announces Renuvion to be Featured in Educational Sessions at the American Academy of Cosmetic Surgery (AACS) Scientific Meeting
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2023 Revenue Results
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation Announces New Debt Facility with Perceptive Advisors
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation to Participate in Upcoming Investor Conferences in November
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2023 Financial Results on November 9, 2023
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation Reports Second Quarter 2023 Financial Results and Reaffirms Full Year 2023 Financial Outlook
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation to Release Second Quarter of Fiscal Year 2023 Financial Results on August 10, 2023
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation Announces FDA 510(k) Clearance for the Renuvion® Micro Handpiece
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion® for Coagulation of Subcutaneous Soft Tissues Following Liposuction for Aesthetic Body Contouring
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2022 Financial Results; Introduces Full Year 2023 Financial Outlook
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion® to Coagulate and Contract Soft Tissues, Including Subcutaneous Tissue, Where Needed
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation Announces New Five-Year Credit Agreement with MidCap Financial
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2022 Financial Results on March 16, 2023
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation Announces FDA 510(k) Submission for the Use of the Renuvion® APR Handpiece for the Coagulation of Subcutaneous Soft Tissues Where Needed, Following Liposuction
From Apyx Medical Corporation
Via Business Wire
News headline image
Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results
From Apyx Medical Corporation
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.